CASE REPORT

Highly aggressive undifferentiated small round blue cell tumor of foot with unique SMARCA1, KAT6A and NAV3 mutations

Cyrus Parsa1,*, Robert Orlando2, Michael Marcus3, Jin Guo1, and Ravin Rupani4

1Department of Pathology, Western University of Health Sciences, 309 E. 2nd St., Pomona, CA, USA, 2Department of Pathology, Beverly Hospital, 309 W. Beverly Blvd., Montebello, CA, USA, 3Department of Surgery, Beverly Hospital, 309 W. Beverly Blvd., Montebello, CA, USA, and 4Department of Internal Medicine, Oncology, Beverly Hospital, 309 W. Beverly Blvd., Montebello, CA, USA

*Correspondence address. Department of Pathology, Western University of Health Sciences, 309 E. 2nd St., Pomona, CA 91766, USA. Tel: 323-889-2414; E-mail: cparsa@westernu.edu

Abstract

Malignancies characterized histologically by high-grade monotonous small round blue cells (SRBCs) belong to a heterogeneous group of neoplasms often referred to as Ewing family of tumors. The most common molecular confirmation of these neoplasms is by fusions between EWSR1 gene on chromosome 22 and the ETS family of transcription factors, including FLI1 gene (11q24) and the ERG (21q22), that are implicated in the development of different tissues as well as cancer progression. In this article, we present a case of highly aggressive extraskeletal SRBC tumor involving the foot of a 24-year-old male with sole molecular findings of mutations in KAT6A, NAV3 and SMARCA1 genes with high expression of soft tissue markers (COL1A1, COL1A2, COL3A1) and MYC mRNA. To our knowledge, this unique mutational pattern has not previously been described in SRBCs.

INTRODUCTION

Malignant neoplasms with high-grade monotonous small round cells, originally described in 1921 as ‘round cell sarcoma’ of unknown origin [1], occur mostly as primary tumors of long tubular bones in children and adolescents but may also be extraskeletal. Histologically similar neoplasms with divergent gene expression patterns are often referred to as Ewing-like family of tumors. These tumors are often associated with some characteristic immunohistochemical, genetic and molecular markers.

Chromosomal translocation-related genetic fusions between EWSR1 on chromosome 22 to the FLI1 gene on chromosome 11 and other genes encoding ETS family of transcription factor (EWS-ETS) are considered a genetic hallmark of human Ewing sarcoma [2–4]. Moreover, the epigenetic status of genes responsive to transcriptional regulation by EWS-ETS is important for Ewing sarcoma development and its phenotypic manifestation [5]. In a retrospective study of a large cohort of unclassified sarcomas with a round cell component, 10% were shown to harbor ‘CIC-DUX4’ or ‘BCOR-CCNB3’ fusions or other ‘CIC’ rearrangements [6]. Undifferentiated small cell sarcomas lacking these molecular and genetic markers, as in this case report, have also been referred to as ‘Ewing-like tumors’ [7].

CASE REPORT

A 27-year-old male presented with 3-month history of ‘callus’ in his left foot, which had increased in size over time, becoming more red, exquisitely tender and painful in the last few days.
The lesion, 1.5 cm in diameter, involved the plantar surface of his forefoot where it was associated with pain described as sharp, increasing in intensity by pressure during walking. The pain decreased with rest but was tender, swollen, warm and red. The patient complained of fever and chills while at home.

On physical examination, the only significant findings included morbid obesity and a 'small red tender lesion' resembling an 'abscess or fluid collection at the bottom of his foot' (Fig. 1). X-ray of the patient's foot was interpreted as 'soft tissue swelling' (Fig. 2). The patient was treated with antibiotics for the initial impression of cellulitis and sepsis.

Surgical consultation revealed a deeply ulcerated cavitary-like mass with gelatinous content. The excised mass, covered by an ellipse of skin, was 5.0 cm × 3.5 cm × 3.5 cm. On section, the mass was 2.5 cm in diameter, pale tan-white with red-brown areas of discoloration. Intraoperative touch preparation of the lesional cut surface was suspicious for small round blue cell (SRBC) tumor (Fig. 3). Microscopic sections of the lesion consisted predominantly of sheets of poorly differentiated malignant neoplastic cells with moderately pleomorphic vesicular nuclei, scant clear cytoplasm and abundant mitotic activity (Fig. 4). The neoplasm extended to the inked surgical margins of resection.

Immunohistochemical stains of the lesion included the following results: (i) vimentin, CD 99, c-MYC and WT1 were diffusely positive; (ii) CD 56 was focally positive and (iii) CD10, CD45, S100, chromogranin, synaptophysin, CK-pan, HMB-45, myogenin, CD34, desmin, ERG and NKX2.2 were all negative.

Next-generation sequencing (NGS) testing of the tumor was negative for expression of fusion RNA or mutations involving EWSR1 gene. Subsequent comprehensive NGS molecular genetics testing of 1400 genes, were negative for any translocations that lead to the expression of fusion RNA, there was no evidence of a fusion RNA. Exons of 1385 cancer genes were sequenced at Neo-Genomics Laboratories (La Jolla, CA) and included 507 genes involved in fusions and more than 850 genes either mutated or deregulated in cancers. In addition, 160 bp of the 5’ and 3’ untranslated regions of every targeted gene were included in this testing.

As an overall summary of the available data and testing of this neoplasm, the following results were noted: (i) negative for specific chromosomal translocations; (ii) no evidence of a fusion mRNA involving CIC, Dux4, BCOR or any of the tested 1400 oncogenes; (iii) negative for SYT genes by
Highly aggressive undifferentiated small round blue cell tumor of foot

Figure 4: Sections of the lesion consist predominantly of sheets of poorly differentiated malignant neoplastic cells with moderately pleomorphic vesicular nuclei, clear cytoplasm, and abundant mitotic activity.

Figure 5: Two months following the excision, the patient presented with a significantly enlarged, necrotic and ulcerated tumor at the excision site.

Figure 6: Repeat lateral X-ray views of the foot, 2 months later, showed ‘interval appearance of large soft tissue mass, plantar to the phalanges’. The differential diagnostic consideration by the imaging studies included ‘phlegmon, abscess, hematoma, or less likely a rapidly growing neoplasm’.

Approximately 2 months following surgical excision of the tumor, the patient presented with a significantly enlarged and painful recurrence of the mass (Fig. 5). Repeat X-rays of the foot showed ‘interval large soft tissue mass’ (Fig. 6). Nuclear three-phase bone scan was ‘suspicious for osteomyelitis or tumor involvement of bone’.

As a follow-up treatment, the patient underwent an above the knee amputation of left lower extremity and was subsequently found to have lung metastases within 1 year of initial diagnosis.

DISCUSSION

In this case of an undifferentiated SRBC tumor, the only mutations identified in the tumor were frame shift variants of SMARCA1, KAT6A and NAV3. All other tests including testing for a fusion RNA, 1400 oncogenes with an NGS Ewing sarcoma fusion profile, were negative. Although aberrant expressions of these frame shift variants have been described in a variety of tumors [8–10], they have not, to our knowledge, been previously described as the sole molecular/genetic findings in an undifferentiated SRBC tumor, especially involving the foot. The rapidly progressive course of this case, possibly partially or totally attributed to the high expression of soft tissue markers (COL1A1, COL1A2, COL3A1) as well as MYC mRNA, is indicative of the very aggressive nature of this tumor. Additional testing with possible retrospective molecular and mutational studies of such SRBC tumors are needed for clarification and understanding of their varied pathogenesis and classification.

CONFLICT OF INTEREST

None declared.
REFERENCES

1. Ewing J. Diffuse endothelioma of bone. Proc New York Pathol Soc 1921;21:17–24.

2. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162–5.

3. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 1993;12:4481–7.

4. Sorensen PH. A second Ewing's sarcoma translocation, t(21,22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994;6:146–51.

5. Tanaka M, Yamazaki Y, Kanno Y, Igarashi K, Aisaki K, Kanno J, et al. Ewing's sarcoma is a precursors are highly enriched in embryonic osteochondrogenic progenitors. J Clin Invest 2014;124:3061–74.

6. Wang WL, Lazar AJ. Undifferentiated blue round cell (Ewing-like) sarcoma: not always so-round nor Ewing-like. Virchows Arch 2017;470:371.

7. Gamberi G, Cocchi S, Benini S, Magagnoli G, Morandi L, Kreshak J, et al. Molecular diagnosis in Ewing family tumors: the Rizzoli experience–222 consecutive cases in four years. J Mol Diagn 2011;13:313–24.

8. Huang F, Abmayr SM, Workman JL. Regulation of KAT6 acetyltransferases and their roles in cell cycle progression, stem cell maintenance, and human disease. Mol Cell Biol 2016;36:1900–7.

9. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013;45:1134–40.

10. Kohashi K, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci 2017;108:547–52.